Latest News
AveXis Presents Data at AAN Annual Meeting Demonstrating Efficacy of Zolgensma in Broad Spectrum of Spinal Muscular Atrophy (SMA) Patients
AveXis, a Novartis company, recently announced interim data from ongoing trials of the investigational product Zolgensma® (onasemnogene abeparvovec-xioi; AVXS-101) that showed positive results across a broad spectrum of patients with […]
Read More ›Cure SMA and Genentech Partner to Provide Travel Support to Adults with SMA the Annual SMA Conference
Cure SMA is thrilled to announce that we will be extending travel scholarship opportunities to adults with SMA (18 and over) who are attending the 2019 Annual SMA Conference, taking […]
Read More ›Biogen to Present Data at AAN Highlighting Spinraza and Emerging Biomarkers for SMA
Biogen today announced it will present new data focusing on SMA at the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA., May 4–11. Results from […]
Read More ›Genentech Presents New Data at the 2019 AAN Annual Meeting
Genentech, a member of the Roche Group, announced today that new data will be presented at the 71st American Academy of Neurology (AAN) Annual Meeting from May 4-10 in Philadelphia, […]
Read More ›Community Spotlight: Kyle and Laura Derkowski
Kyle and Laura Derkowski are co-chairs of the Cure SMA Virginia Chapter. The pair met during their first year in college through a mutual friend and were married in December […]
Read More ›Biogen Presents New Data Regarding Adults and Infants with SMA
Biogen has announced it will present new data illustrating the rapidly progressive nature of spinal muscular atrophy (SMA) in adults, adolescents and older children at the Muscular Dystrophy Association (MDA) […]
Read More ›